Aelix Therapeutics, based in Barcelona, is a spin-off of the HIVACAT vaccine research consortium. The company focuses on the discovery and development of immunotherapies against HIV infection. A first round of funding (11.5 million euros) was closed in January 2016. A phase II proof-of-concept clinical trial using the HTI immunogen as a therapeutic vaccine in people with HIV infection is foreseen to be completed by 2020. 

Read the news on the Aelix Therapeutics constitution.